Trials / Completed
CompletedNCT00726856
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,200 (estimated)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. This study assesses the percentage of patients who achieve LDL-C target goals and also evaluates the patient compliance to treatment.
Detailed description
Retrospective medical chart review
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate | Ezetimibe 10 mg taken daily for 3 months |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2008-08-01
- Last updated
- 2022-02-16
Source: ClinicalTrials.gov record NCT00726856. Inclusion in this directory is not an endorsement.